Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease

Priti Gros¹, Susan H Fox^{1

2}, Anthony E Lang^{1

2}

Affiliations

¹ Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
² Krembil Brain Institute, Toronto, Ontario, Canada.

Comment

Priti Gros et al. JAMA Neurol. 2022.

. 2022 Jul 1;79(7):726.

doi: 10.1001/jamaneurol.2022.1601.

Priti Gros¹, Susan H Fox^{1

2}, Anthony E Lang^{1

2}

¹ Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
² Krembil Brain Institute, Toronto, Ontario, Canada.

No abstract available

Comment in

Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease-Reply.
Gray R, Jenkinson C, Clarke CE. Gray R, et al. JAMA Neurol. 2022 Jul 1;79(7):726-727. doi: 10.1001/jamaneurol.2022.1604. JAMA Neurol. 2022. PMID: 35759259 No abstract available.

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.